Cargando…

Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utili...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawhn-Heath, Courtney, Yom, Sue S., Liu, Chienying, Villanueva-Meyer, Javier E., Aslam, Maya, Smith, Raven, Narwal, Manpreet, Juarez, Roxanna, Behr, Spencer C., Pampaloni, Miguel Hernandez, Chan, Jason W., Glastonbury, Christine M., Hope, Thomas A., Flavell, Robert R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581659/
https://www.ncbi.nlm.nih.gov/pubmed/33090273
http://dx.doi.org/10.1186/s13550-020-00720-3
_version_ 1783599018134208512
author Lawhn-Heath, Courtney
Yom, Sue S.
Liu, Chienying
Villanueva-Meyer, Javier E.
Aslam, Maya
Smith, Raven
Narwal, Manpreet
Juarez, Roxanna
Behr, Spencer C.
Pampaloni, Miguel Hernandez
Chan, Jason W.
Glastonbury, Christine M.
Hope, Thomas A.
Flavell, Robert R.
author_facet Lawhn-Heath, Courtney
Yom, Sue S.
Liu, Chienying
Villanueva-Meyer, Javier E.
Aslam, Maya
Smith, Raven
Narwal, Manpreet
Juarez, Roxanna
Behr, Spencer C.
Pampaloni, Miguel Hernandez
Chan, Jason W.
Glastonbury, Christine M.
Hope, Thomas A.
Flavell, Robert R.
author_sort Lawhn-Heath, Courtney
collection PubMed
description BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [(68)Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. METHODS: Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[(18)F]FDG PET and/or (131)I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [(68)Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[(18)F]FDG PET CT/MRI for lesion location and relative intensity. RESULTS: Twelve patients underwent [(68)Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[(18)F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[(18)F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. CONCLUSIONS: [(68)Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[(18)F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients.
format Online
Article
Text
id pubmed-7581659
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-75816592020-10-26 Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study Lawhn-Heath, Courtney Yom, Sue S. Liu, Chienying Villanueva-Meyer, Javier E. Aslam, Maya Smith, Raven Narwal, Manpreet Juarez, Roxanna Behr, Spencer C. Pampaloni, Miguel Hernandez Chan, Jason W. Glastonbury, Christine M. Hope, Thomas A. Flavell, Robert R. EJNMMI Res Original Research BACKGROUND: Prostate-specific membrane antigen (PSMA) is expressed in the microvasculature of thyroid cancer. This suggests the potential use of PSMA as a diagnostic agent in patients with aggressive forms of thyroid cancer. The purpose of the current study was to determine the feasibility and utility of [(68)Ga]Ga-PSMA-11 PET/MRI in thyroid cancer patients. METHODS: Eligible patients for this prospective pilot study were adults with a history of pathology-proven thyroid cancer who had abnormal radiotracer uptake on an 2-[(18)F]FDG PET and/or (131)I scintigraphy performed in the 12 months prior to study enrollment. Patients underwent a [(68)Ga]Ga-PSMA-11 PET/MRI, and comparison was made to the prior qualifying 2-[(18)F]FDG PET CT/MRI for lesion location and relative intensity. RESULTS: Twelve patients underwent [(68)Ga]Ga-PSMA-11 PET/MRI, one of which was excluded from analysis due to debulking surgery prior to the PSMA PET. Of the remaining patients, 7/11 had differentiated disease (3 papillary, 2 follicular, 2 Hurthle cell) and 4/11 had dedifferentiated disease (2 poorly differentiated papillary, 2 anaplastic). Out of 43 lesions, 41 were visually 2-[(18)F]FDG positive (uptake greater than background, detection rate 95.3%) and 28 were PSMA positive (uptake greater than background, detection rate 65.1%). Uptake was heterogeneous between patients, and in some cases within patients. 3/11 patients (1 poorly differentiated papillary, 2 follicular) had PSMA uptake which was greater than FDG uptake. For the remaining 8 patients, 2-[(18)F]FDG uptake was greater than PSMA. Using one eligibility guideline in the prostate cancer literature for PSMA radioligand therapy (RLT), 8/11 could be considered eligible for possible future PSMA RLT. This was not predictable based on thyroid cancer subtype. CONCLUSIONS: [(68)Ga]Ga-PSMA-11 PET demonstrated lower detection rate when compared to 2-[(18)F]FDG PET for thyroid cancer lesion visualization. Thyroid cancer subtype alone may not be sufficient to predict PSMA uptake, and radiotracer uptake may vary between patients and even within patients. Springer Berlin Heidelberg 2020-10-22 /pmc/articles/PMC7581659/ /pubmed/33090273 http://dx.doi.org/10.1186/s13550-020-00720-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Research
Lawhn-Heath, Courtney
Yom, Sue S.
Liu, Chienying
Villanueva-Meyer, Javier E.
Aslam, Maya
Smith, Raven
Narwal, Manpreet
Juarez, Roxanna
Behr, Spencer C.
Pampaloni, Miguel Hernandez
Chan, Jason W.
Glastonbury, Christine M.
Hope, Thomas A.
Flavell, Robert R.
Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title_full Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title_fullStr Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title_full_unstemmed Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title_short Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
title_sort gallium-68 prostate-specific membrane antigen ([(68)ga]ga-psma-11) pet for imaging of thyroid cancer: a feasibility study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581659/
https://www.ncbi.nlm.nih.gov/pubmed/33090273
http://dx.doi.org/10.1186/s13550-020-00720-3
work_keys_str_mv AT lawhnheathcourtney gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT yomsues gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT liuchienying gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT villanuevameyerjaviere gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT aslammaya gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT smithraven gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT narwalmanpreet gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT juarezroxanna gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT behrspencerc gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT pampalonimiguelhernandez gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT chanjasonw gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT glastonburychristinem gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT hopethomasa gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy
AT flavellrobertr gallium68prostatespecificmembraneantigen68gagapsma11petforimagingofthyroidcancerafeasibilitystudy